Sarcopenia, muscle mass, protein, Neuromuscular electrostimulation
Conditions
Interventions
Consumption of a 40 g bolus of intrinsically L[1-13C]-phenylalanine labeled casein protein and 70 min of one-legged NMES.
Sponsors
Prof. LJC van Loon
Maastricht University
Department of Human Movement Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent; 2. Age ≥ 65 years; 3. Male.
Exclusion criteria
Exclusion criteria: 1. Type II diabetes; 2. All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders, paralysis, hip/knee surgery); 3. Use of anticoagulants, blood diseases, allergy for lidocain; 4. Use of NSAIDs and acetylsalicylic acid; 5. Patients suffering from PKU (Phenylketonuria); 6. Presence of implantable cardioverter defibrillator and/or pacemaker; 7. Performed regular resistance type exercise in the past 6 months; 8. Use of any tools to assist during walking (cane/ crutches/ walker); 9. (Partial) foot/ leg amputation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary parameter of this study will be overnight incorporation of stable isotope amino acids from the intrinsically labeled drink. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary parameter of this study will be plasma amino acid enrichment after ingestion of the intrinsically labeled protein. | — |
Contacts
Public ContactB. Groen
Outcome results
None listed